Icos (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Icos" in English language version.

Last modified: 19:39:30, 12 August 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

3917web.archive.org

1^st place

2913seattletimes.com

449^th place

222^nd place

166seattlepi.com

1,619^th place

867^th place

106nwsource.com

1,828^th place

1,227^th place

105nytimes.com

7^th place

98doi.org

2^nd place

87nih.gov

5^th place

72washingtonpost.com

35^th place

24^th place

51sec.gov

617^th place

437^th place

33semanticscholar.org

15^th place

8^th place

22clinicaltrials.gov

4,259^th place

3,081^st place

22bizjournals.com

396^th place

190^th place

11twst.com

low place

11reuters.com

38^th place

30^th place

11pqarchiver.com

846^th place

502^nd place

11uspto.gov

2,155^th place

1,380^th place

11books.google.com

3^rd place

11fda.gov

470^th place

329^th place

11jbc.org

6,339^th place

9,753^rd place

11adsabs.harvard.edu

14^th place

9^th place

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

ui.adsabs.harvard.edu

Tjoelker T, et al. (April 6, 1995). "Anti-inflammatory properties of a platelet-activating factor acetylhydrolase". Nature. 374 (6522): 549–53. Bibcode:1995Natur.374..549T. doi:10.1038/374549a0. PMID 7700381. S2CID 4338858.

bizjournals.com (Global: 396^th place; English: 190^th place)

seattle.bizjournals.com

"Icos Psoriasis Treatment Falls Short". Puget Sound Business Journal. June 6, 2003. Retrieved January 10, 2009.
"Icos to manufacture antibodies for German biotech". Puget Sound Business Journal. November 26, 2001. Retrieved August 16, 2009.

books.google.com (Global: 3^rd place; English: 3^rd place)

Mohr, J. P.; Choi, Dennis W.; Grotta, James C. (2004). Stroke: pathophysiology, diagnosis, and management. Elsevier Health Sciences. pp. 1044–1045. ISBN 978-0-443-06600-9. Retrieved August 16, 2009.

clinicaltrials.gov (Global: 4,259^th place; English: 3,081^st place)

"PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension". ClinicalTrials.gov. February 13, 2008. Retrieved May 30, 2009.
"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of RTX Topical Solution in Patients With Interstitial Cystitis". ClinicalTrials.gov. June 23, 2005. Retrieved August 16, 2009.

doi.org (Global: 2^nd place; English: 2^nd place)

Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H, Kirilovsky J, Hyafil F, Labaudinière R (October 9, 2003). "The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues". Journal of Medicinal Chemistry. 46 (21): 4525–32. doi:10.1021/jm030056e. PMID 14521414.
Becker K (August 2002). "Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke". Current Medical Research and Opinion. 18 (Suppl 2): s18–22. doi:10.1185/030079902125000688. PMID 12365824. S2CID 35685091.
Schuster DP, Metzler M, Opal S, Lowry S, Balk R, Abraham E, Levy H, Slotman G, Coyne E, Souza S, Pribble J (June 2003). "Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial". Critical Care Medicine. 31 (6): 1612–9. doi:10.1097/01.CCM.0000063267.79824.DB. PMID 12794395.
Stafforini DM, McIntyre TM, Carter ME, Prescott SM (March 25, 1987). "Human Plasma Platelet-activating Factor Acetylhydrolase". Journal of Biological Chemistry. 262 (9): 4215–22. doi:10.1016/S0021-9258(18)61335-3. PMID 3549727. Archived from the original on January 8, 2016. Retrieved September 4, 2009.
Tjoelker T, et al. (April 6, 1995). "Anti-inflammatory properties of a platelet-activating factor acetylhydrolase". Nature. 374 (6522): 549–53. Bibcode:1995Natur.374..549T. doi:10.1038/374549a0. PMID 7700381. S2CID 4338858.
Stafforini DM (February 2009). "Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)". Cardiovascular Drugs and Therapy. 23 (1): 73–83. doi:10.1007/s10557-008-6133-8. PMID 18949548. S2CID 21413645.
Ligocki M, Mackeen L, Axtelle T, Trueblood E, Hensley K, Stucki A, Sandmaier BM, Hayflick JS (July 1, 2000). "Anti-tumor activity of an ICAM-3 antibody (ICM3) against human leukemic xenograft tumors in nude mice". Experimental Hematology. 28 (7): 59–60. doi:10.1016/S0301-472X(00)00274-5.
Axtelle T, Pribble J (August 2001). "IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis". Journal of Endotoxin Research. 7 (4): 310–4. doi:10.1177/09680519010070040201. PMID 11717588.

fda.gov (Global: 470^th place; English: 329^th place)

"Community consultation and public disclosure information for waiver of Informed Consent" (PDF). Food and Drug Administration. August 27, 1998. Archived from the original (PDF) on June 6, 2011. Retrieved January 12, 2009.

jbc.org (Global: 6,339^th place; English: 9,753^rd place)

Stafforini DM, McIntyre TM, Carter ME, Prescott SM (March 25, 1987). "Human Plasma Platelet-activating Factor Acetylhydrolase". Journal of Biological Chemistry. 262 (9): 4215–22. doi:10.1016/S0021-9258(18)61335-3. PMID 3549727. Archived from the original on January 8, 2016. Retrieved September 4, 2009.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H, Kirilovsky J, Hyafil F, Labaudinière R (October 9, 2003). "The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues". Journal of Medicinal Chemistry. 46 (21): 4525–32. doi:10.1021/jm030056e. PMID 14521414.
Becker K (August 2002). "Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke". Current Medical Research and Opinion. 18 (Suppl 2): s18–22. doi:10.1185/030079902125000688. PMID 12365824. S2CID 35685091.
Schuster DP, Metzler M, Opal S, Lowry S, Balk R, Abraham E, Levy H, Slotman G, Coyne E, Souza S, Pribble J (June 2003). "Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial". Critical Care Medicine. 31 (6): 1612–9. doi:10.1097/01.CCM.0000063267.79824.DB. PMID 12794395.
Stafforini DM, McIntyre TM, Carter ME, Prescott SM (March 25, 1987). "Human Plasma Platelet-activating Factor Acetylhydrolase". Journal of Biological Chemistry. 262 (9): 4215–22. doi:10.1016/S0021-9258(18)61335-3. PMID 3549727. Archived from the original on January 8, 2016. Retrieved September 4, 2009.
Tjoelker T, et al. (April 6, 1995). "Anti-inflammatory properties of a platelet-activating factor acetylhydrolase". Nature. 374 (6522): 549–53. Bibcode:1995Natur.374..549T. doi:10.1038/374549a0. PMID 7700381. S2CID 4338858.
Stafforini DM (February 2009). "Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)". Cardiovascular Drugs and Therapy. 23 (1): 73–83. doi:10.1007/s10557-008-6133-8. PMID 18949548. S2CID 21413645.
Axtelle T, Pribble J (August 2001). "IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis". Journal of Endotoxin Research. 7 (4): 310–4. doi:10.1177/09680519010070040201. PMID 11717588.

nwsource.com (Global: 1,828^th place; English: 1,227^th place)

seattletimes.nwsource.com

Timmerman, Luke (December 7, 2006). "Icos starts trial of drug, opts not to disclose it". The Seattle Times. Retrieved August 16, 2008.
Timmerman, Luke (January 13, 2007). "Reject Icos offer, holders of shares advised". The Seattle Times. p. E1. Retrieved January 17, 2009.
"Eli Lilly completes Icos takeover". The Seattle Times. January 30, 2007. p. C1. Retrieved January 17, 2009.
Timmerman, Luke (December 12, 2006). "All Icos workers losing their jobs". The Seattle Times. p. C1. Retrieved January 16, 2008.
Timmerman, Luke (November 2, 2006). "Icos leaders to get $68 million from company's sale". The Seattle Times. p. C1. Retrieved January 16, 2008.

archives.seattletimes.nwsource.com

Timmerman, Luke (November 7, 2006). "Proposed Icos sale gets more criticism: Payouts for execs called "overkill"". The Seattle Times. p. C1. Retrieved January 16, 2008.

nytimes.com (Global: 7^th place; English: 7^th place)

query.nytimes.com

Pollack, Andrew (October 2, 1998). "Lilly Pays Big Fee Up Front To Share in Rival of Viagra". The New York Times. p. C5. Retrieved January 12, 2009.
"British Court Overturns a Viagra Patent". The New York Times. November 9, 2000. p. C10. Retrieved January 13, 2009.
Elliott, Stuart (April 25, 2004). "Viagra and the Battle of the Awkward Ads". The New York Times. p. 1. Retrieved January 15, 2009.

nytimes.com

Elliott, Stuart (January 10, 2006). "For Impotence Drugs, Less Wink-Wink". The New York Times. p. C2. Retrieved January 15, 2009.
"Lilly Increases Offer for Icos; Shareholders' Vote Is Put Off". The New York Times. December 19, 2006. p. C10. Retrieved January 16, 2008.

pqarchiver.com (Global: 846^th place; English: 502^nd place)

pqasb.pqarchiver.com

Rosenwald, Michael (June 1, 2009). "Local Drugmaker Found Great Partner in Eli Lilly". The Washington Post. p. A10. Archived from the original on June 4, 2011. Retrieved August 16, 2009.

reuters.com (Global: 38^th place; English: 30^th place)

Hirschler, Ben (June 25, 2007). "Europe Approves Once-Daily Cialis For Impotence". Reuters. Retrieved January 24, 2009.

seattlepi.com (Global: 1,619^th place; English: 867^th place)

Tartakoff, Joseph (December 4, 2007). "New owner will invest $50 million in Icos facility". Seattle Post-Intelligencer. p. E1. Retrieved January 17, 2009.
Erickson, Jim (July 3, 1990). "Top Scientists Form Biotech Firm; Gates is Largest Shareholder as Investors Come Up With $33 Million". Seattle Post-Intelligencer. p. A1. Archived from the original on August 15, 2018. Retrieved January 24, 2009.
Cook, John (November 22, 2003). "36-hour Erection Drug Cialis Gets U.S. Approval". Seattle Post-Intelligencer. p. A1. Retrieved January 10, 2009.
"Tech Briefs". Seattle Post-Intelligencer. November 6, 2001. p. D2. Retrieved January 12, 2009.
James, Andrea (January 26, 2007). "Icos voters approve buyout by Eli Lilly". Seattle Post-Intelligencer. p. C1. Retrieved January 17, 2009.
Cook, John (October 20, 2006). "Icos' gain is Seattle's loss". Seattle Post-Intelligencer. p. C1. Archived from the original on August 15, 2018. Retrieved January 17, 2009.

seattletimes.com (Global: 449^th place; English: 222^nd place)

archive.seattletimes.com

Ervin, Keith (June 21, 1998). "Deep Pockets + Intense Research + Total Control = The Formula—Bothell Biotech Icos Keeps The Pipeline Full Of Promise". The Seattle Times. p. F1. Archived from the original on February 24, 2012. Retrieved January 10, 2009.
Timmerman, Luke (October 18, 2006). "Icos Sale a Blow to Local Biotech". The Seattle Times. p. A1. Archived from the original on September 15, 2012. Retrieved January 10, 2009.
Lee, Tyrone (February 2, 2000). "Guiding Father of Icos Cuts Cord". The Seattle Times. p. E1. Archived from the original on September 27, 2012. Retrieved January 10, 2009.
"Icos Names Paul Clark President, Chief Executive". The Seattle Times. June 16, 1999. Archived from the original on September 27, 2012. Retrieved August 30, 2009.
Reed, Kristin (June 15, 1999). "Icos Shares Skid After Drug Fails Test in Treating Shock". The Seattle Times. p. C7. Archived from the original on September 15, 2012. Retrieved January 10, 2009.
"Icos Halts Stroke-Drug Study After Late Results Disappoint". The Seattle Times. April 21, 2000. p. C6. Archived from the original on September 15, 2012. Retrieved January 10, 2009.
"Icos Drug Pafase Hits a Dead End". The Seattle Times. December 20, 2002. p. D1. Archived from the original on September 23, 2012. Retrieved January 10, 2009.
Timmerman, Luke (December 16, 2006). "Another Clinical Trial Near From Icos Pipeline". The Seattle Times. p. E1. Retrieved January 10, 2009.
Beason, Tyrone (June 7, 2000). "Icos teams with Texas biotech for drug trials". The Seattle Times. p. C3. Archived from the original on September 27, 2012. Retrieved January 15, 2009.
"Bothell biotech's partner makes additional investment". The Seattle Times. April 24, 2003. p. E3. Archived from the original on September 27, 2012. Retrieved January 15, 2009.
Timmerman, Luke (January 14, 2004). "Icos chief stirs up interest in Cialis at investor event". The Seattle Times. p. E1. Archived from the original on September 27, 2012. Retrieved January 12, 2009.
"Microsoft again presses for court delay". The Seattle Times. August 15, 2001. Archived from the original on September 27, 2012. Retrieved August 16, 2009.

old.seattletimes.com

Timmerman, Luke (October 21, 2006). "Icos sale to enrich top executives". The Seattle Times. p. E1. Retrieved January 16, 2008.

sec.gov (Global: 617^th place; English: 437^th place)

"ICOS Corporation Annual Report". Securities and Exchange Commission. March 8, 2006. Archived from the original on August 27, 2017. Retrieved January 17, 2009.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Becker K (August 2002). "Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke". Current Medical Research and Opinion. 18 (Suppl 2): s18–22. doi:10.1185/030079902125000688. PMID 12365824. S2CID 35685091.
Tjoelker T, et al. (April 6, 1995). "Anti-inflammatory properties of a platelet-activating factor acetylhydrolase". Nature. 374 (6522): 549–53. Bibcode:1995Natur.374..549T. doi:10.1038/374549a0. PMID 7700381. S2CID 4338858.
Stafforini DM (February 2009). "Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)". Cardiovascular Drugs and Therapy. 23 (1): 73–83. doi:10.1007/s10557-008-6133-8. PMID 18949548. S2CID 21413645.

twst.com (Global: low place; English: low place)

"Interview with George Rathmann, Icos Corporation". The Wall Street Transcript. April 27, 1999. Retrieved March 17, 2009.

uspto.gov (Global: 2,155^th place; English: 1,380^th place)

portal.uspto.gov

"Non-final Office Action" (PDF). United States Patent and Trademark Office. September 15, 2005. Retrieved August 19, 2009. Use 90/007,478 for the application number.

washingtonpost.com (Global: 35^th place; English: 24^th place)

Kaufman, Marc (July 1, 2005). "FDA Was Told of Viagra-Blindness Link Months Ago; Senator Criticizes Delay in Alerting Consumers After Safety Officer Warned Agency About Drug". The Washington Post. p. A02. Retrieved January 24, 2009.
Kaufman, Marc (July 9, 2005). "Impotence Drugs Will Get Blindness Warning". The Washington Post. p. A06. Retrieved January 24, 2009.

web.archive.org (Global: 1^st place; English: 1^st place)

"ICOS Corporation Annual Report". Securities and Exchange Commission. March 8, 2006. Archived from the original on August 27, 2017. Retrieved January 17, 2009.
Ervin, Keith (June 21, 1998). "Deep Pockets + Intense Research + Total Control = The Formula—Bothell Biotech Icos Keeps The Pipeline Full Of Promise". The Seattle Times. p. F1. Archived from the original on February 24, 2012. Retrieved January 10, 2009.
Timmerman, Luke (October 18, 2006). "Icos Sale a Blow to Local Biotech". The Seattle Times. p. A1. Archived from the original on September 15, 2012. Retrieved January 10, 2009.
Erickson, Jim (July 3, 1990). "Top Scientists Form Biotech Firm; Gates is Largest Shareholder as Investors Come Up With $33 Million". Seattle Post-Intelligencer. p. A1. Archived from the original on August 15, 2018. Retrieved January 24, 2009.
Lee, Tyrone (February 2, 2000). "Guiding Father of Icos Cuts Cord". The Seattle Times. p. E1. Archived from the original on September 27, 2012. Retrieved January 10, 2009.
"Icos Names Paul Clark President, Chief Executive". The Seattle Times. June 16, 1999. Archived from the original on September 27, 2012. Retrieved August 30, 2009.
Rosenwald, Michael (June 1, 2009). "Local Drugmaker Found Great Partner in Eli Lilly". The Washington Post. p. A10. Archived from the original on June 4, 2011. Retrieved August 16, 2009.
Reed, Kristin (June 15, 1999). "Icos Shares Skid After Drug Fails Test in Treating Shock". The Seattle Times. p. C7. Archived from the original on September 15, 2012. Retrieved January 10, 2009.
"Community consultation and public disclosure information for waiver of Informed Consent" (PDF). Food and Drug Administration. August 27, 1998. Archived from the original (PDF) on June 6, 2011. Retrieved January 12, 2009.
"Icos Halts Stroke-Drug Study After Late Results Disappoint". The Seattle Times. April 21, 2000. p. C6. Archived from the original on September 15, 2012. Retrieved January 10, 2009.
"Icos Drug Pafase Hits a Dead End". The Seattle Times. December 20, 2002. p. D1. Archived from the original on September 23, 2012. Retrieved January 10, 2009.
Stafforini DM, McIntyre TM, Carter ME, Prescott SM (March 25, 1987). "Human Plasma Platelet-activating Factor Acetylhydrolase". Journal of Biological Chemistry. 262 (9): 4215–22. doi:10.1016/S0021-9258(18)61335-3. PMID 3549727. Archived from the original on January 8, 2016. Retrieved September 4, 2009.
Beason, Tyrone (June 7, 2000). "Icos teams with Texas biotech for drug trials". The Seattle Times. p. C3. Archived from the original on September 27, 2012. Retrieved January 15, 2009.
"Bothell biotech's partner makes additional investment". The Seattle Times. April 24, 2003. p. E3. Archived from the original on September 27, 2012. Retrieved January 15, 2009.
Timmerman, Luke (January 14, 2004). "Icos chief stirs up interest in Cialis at investor event". The Seattle Times. p. E1. Archived from the original on September 27, 2012. Retrieved January 12, 2009.
"Microsoft again presses for court delay". The Seattle Times. August 15, 2001. Archived from the original on September 27, 2012. Retrieved August 16, 2009.
Cook, John (October 20, 2006). "Icos' gain is Seattle's loss". Seattle Post-Intelligencer. p. C1. Archived from the original on August 15, 2018. Retrieved January 17, 2009.

Icos (English Wikipedia)

adsabs.harvard.edu (Global: 14th place; English: 9th place)

ui.adsabs.harvard.edu

bizjournals.com (Global: 396th place; English: 190th place)

seattle.bizjournals.com

books.google.com (Global: 3rd place; English: 3rd place)

clinicaltrials.gov (Global: 4,259th place; English: 3,081st place)

doi.org (Global: 2nd place; English: 2nd place)

fda.gov (Global: 470th place; English: 329th place)

jbc.org (Global: 6,339th place; English: 9,753rd place)

nih.gov (Global: 5th place; English: 5th place)